Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Authors Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Published 15 January 2008 Volume 2007:3(6) Pages 999—1001

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Department of Medical Biotechnologies and Forensic Medicine, Faculty of Medicine, University of Palermo, Italy

Background: This is an observational study undertaken in aim to evaluate the association between metabolic syndrome (MS) and high homocysteinemia (HHcy) in relation with cardiovascular disease (CVD).

Methods: The study involved 126 subjects with angiographically documented CVD and 65 healthy subjects. MS has been diagnosed according to the ATP III criteria and plasma homocysteine concentration has been evaluated.

Results: In patients with CVD the prevalence of MS and HHcy is 17.4% and 25.4% respectively; MS coexists with HHcy in 67.2% of patients; analogous results can be observed among men and women. HHcy and MS are associated with CVD (OR 2.53, 95% CI 1.95–12.43 and OR 5.74, 95% CI 2.67–12.34 respectively) but the presence of the two conditions gives rise to a stronger increase in CVD risk (OR 13.11, 95% CI 5.27–32.06).

Conclusions: Our data suggest that HHcy and MS could work together in increasing CVD risk.
Keywords: homocysteine, metabolic syndrome, cardiovascular disease

Download Article [PDF] 

Readers of this article also read:

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease

Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM

International Journal of Nanomedicine 2014, 9:2677-2687

Published Date: 27 May 2014


Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2013, 9:1-2

Published Date: 27 December 2012

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J

International Journal of Nanomedicine 2012, 7:5053-5065

Published Date: 19 September 2012

Percutaneous coronary intervention of a single coronary artery arising from the right sinus of Valsalva

Mehmet Akif Cakar, Ersan Tatli, Bilhan Ozalp, et al

Vascular Health and Risk Management 2010, 6:1077-1078

Published Date: 25 November 2010

The role of duloxetine in the treatment of anxiety disorders

Domenico De Berardis, Nicola Serroni, Alessandro Carano, Marco Scali, Alessandro Valchera, et al

Neuropsychiatric Disease and Treatment 2008, 4:929-935

Published Date: 10 October 2008

Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease

Gjumrakch Aliev, Eldar Gasimov, Mark E Obrenovich, Kathryn Fischbach, Justin C Shenk, et al

Vascular Health and Risk Management 2008, 4:721-730

Published Date: 6 June 2008

Genetics of chronic obstructive pulmonary disease

Carola Seifart, Alexandra Plagens

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:541-550

Published Date: 15 January 2008

Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents

Mariagrazia Di Marco, Claudia Sadun, Marc Port, Irene Guilbert, Patrick Couvreur

International Journal of Nanomedicine 2007, 2:609-622

Published Date: 15 January 2008

Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction

Lena Björck, Catharina Welin, Annika Rosengren

Vascular Health and Risk Management 2007, 3:1045-1051

Published Date: 15 January 2008